iSpecimen Inc. (ISPC) Fair Value 2026

ISPC · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 2 models active

Value Trap Risk

DANGER (63/100)

Quick Summary — As of 2026-08-27, iSpecimen Inc. (ISPC) trades at $1.60, versus a $4.29 median fair value across its 2 active models — 168.1% above the current price. QOC: 4.8/10. Value Trap Risk: 63/100 (DANGER). 2/13 models active.

Key Facts

Ticker
ISPC
Price
$1.60
Quality Score
4.8/10
Value Trap Risk
63/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +242.8% upside with 49% confidence
Risk: Value Trap score of 63 suggests caution despite apparent undervaluation

Is iSpecimen Inc. (ISPC) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, iSpecimen Inc. (ISPC) appears undervalued as of : the median of 2 independent fair value estimates is $4.29, 168.1% above the current price of $1.60. Estimates range from $3.09 to $5.49. ISPC scores 4.8/10 on fundamental quality and 63/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ISPC’s +168.1% gap is wider than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy iSpecimen Inc. Stock in 2026? →

What Fair Value Does Each Model Give ISPC?

2 Intrinsic Value Models vs. Current Price ($1.60)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $5.49 +242.8%
Asset-Based · Medium Conviction
 $3.09 +93.4%

All Models Active

All 2 models are displayed above.

What Is iSpecimen Inc. (ISPC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for iSpecimen Inc.. Trading at $1.60 against an estimated intrinsic value of $4.29, 2 of 2 active models flag meaningful upside of +168.1% at the median. The most optimistic model, ML-RIV, places fair value at $5.49 (+242.8%), while Dynamic NAV — the most conservative — estimates $3.09 (+93.4%). This +149.4% gap reflects genuine analytical uncertainty about iSpecimen Inc.'s intrinsic worth.

What Do the Models Say About ISPC?

2 of 13 models are currently active for ISPC. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for ISPC is $4.29 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does ISPC Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, ISPC ranks #43 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

Within the Diagnostics & Research space, iSpecimen Inc. competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ISPC a Value Trap?

CirclFi's Value Trap algorithm assigns ISPC a score of 63/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for iSpecimen Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, iSpecimen Inc. is rated at 4.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses. Notably, value trap risk is elevated.

The gap between the most bullish and bearish model spans +149.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ISPC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ISPC's 2 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy iSpecimen Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

BIAFbioAffinity Technologies, Inc.QOC 5.0FRNMFreenome, Inc.QOC 4.8ADVBAdvanced Biomed Inc.QOC 5.0PRPHProPhase Labs, Inc.QOC 4.8XWELXWELL, Inc.QOC 5.5NSTMNovelStem International Corp.QOC 4.2VCYTVeracyte, Inc.QOC 8.8NTRANatera, Inc.QOC 7.5MYGNMyriad Genetics, Inc.QOC 6.6IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: BIAF · FRNM · ADVB · PRPH · XWEL · NSTM · VCYT · NTRA · MYGN · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to ISPC?

7 companies across all industries closest to ISPC’s Quality of Company score of 4.8/10.

BICXBioCorRx Inc.QOC 4.9TPTSTPTSQOC 4.8GDCGD Culture Group LimitedQOC 4.9VVRInvesco Senior Income TrustQOC 4.8MBOTMicrobot Medical Inc.QOC 4.9MPLTMapLight Therapeutics, Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BICX · TPTS · GDC · VVR · MBOT · MPLT · NVDA

What Else Do Investors Ask About iSpecimen Inc.’s Valuation?

What is iSpecimen Inc.'s intrinsic value in 2026?

CirclFi puts iSpecimen Inc. (ISPC)'s intrinsic value at $4.29 — the median of 2 independent model estimates as of 2026-08-27, ranging from $3.09 to $5.49. The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ISPC overvalued or undervalued right now?

At $1.60, 2 of 2 active models suggest ISPC may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $4.29, 168.1% above the current price of $1.60 — a consensus view that ISPC is undervalued. The assessment depends on which methodology best fits iSpecimen Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 4.8 mean for ISPC?

iSpecimen Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ISPC?

CirclFi analyzes ISPC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ISPC a value trap in 2026?

iSpecimen Inc.'s Value Trap score is 63/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, iSpecimen Inc. (ISPC) has a median fair value of $4.29 — 168.1% above the current price of $1.60 — as of 2026-08-27.” Source: circlfi.com/stock/ISPC/ · Methodology
Primary sources for this ISPC valuation
  • Financial statements: iSpecimen Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001558569) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ISPC as of ; valuations recomputed .